• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物警戒中用于病例系列识别和不良事件概况的一致性聚类分析

Consensus clustering for case series identification and adverse event profiles in pharmacovigilance.

作者信息

Norén G Niklas, Meldau Eva-Lisa, Chandler Rebecca E

机构信息

Uppsala Monitoring Centre, Uppsala, Sweden.

Uppsala Monitoring Centre, Uppsala, Sweden.

出版信息

Artif Intell Med. 2021 Dec;122:102199. doi: 10.1016/j.artmed.2021.102199. Epub 2021 Oct 22.

DOI:10.1016/j.artmed.2021.102199
PMID:34823833
Abstract

OBJECTIVE

To describe and evaluate vigiGroup - a consensus clustering algorithm which can identify groups of individual case reports referring to similar suspected adverse drug reactions and describe associated adverse event profiles, accounting for co-reported adverse event terms.

MATERIALS AND METHODS

Consensus clustering is achieved by grouping pairs of reports that are repeatedly placed together in the same clusters across a set of mixture model-based cluster analyses. The latter use empirical Bayes statistical shrinkage for improved performance. As baseline comparison, we considered a regular mixture model-based cluster analysis. Three randomly selected drugs in VigiBase, the World Health Organization's global database of Individual Case Safety Reports were analyzed: sumatriptan, ambroxol and tacrolimus. Clustering stability was assessed using the adjusted Rand index, ranging between -1 and +1, and clinical coherence was assessed through an intruder detection analysis.

RESULTS

For the three drugs considered, vigiGroup achieved stable and coherent results with adjusted Rand indices between +0.80 and +0.92, and intruder detection rates between 86% and 94%. Consensus clustering improved both stability and clinical coherence compared to mixture model-based clustering alone. Statistical shrinkage improved the stability of clusters compared to the baseline mixture model, as well as the cross-validated log-likelihood.

CONCLUSIONS

The proposed algorithm can achieve adequate stability and clinical coherence in clustering individual case reports, thereby enabling better identification of case series and associated adverse event profiles in pharmacovigilance. The use of empirical Bayes shrinkage and consensus clustering each led to meaningful improvements in performance.

摘要

目的

描述和评估vigiGroup——一种共识聚类算法,该算法能够识别涉及相似疑似药物不良反应的个体病例报告组,并描述相关的不良事件概况,同时考虑共同报告的不良事件术语。

材料与方法

通过对一组基于混合模型的聚类分析中反复被归为同一聚类的报告对进行分组来实现共识聚类。后者使用经验贝叶斯统计收缩法以提高性能。作为基线比较,我们考虑了基于常规混合模型的聚类分析。对世界卫生组织全球个体病例安全报告数据库VigiBase中随机选择的三种药物进行了分析:舒马曲坦、氨溴索和他克莫司。使用调整后的兰德指数评估聚类稳定性,范围在-1至+1之间,并通过入侵者检测分析评估临床一致性。

结果

对于所考虑的三种药物,vigiGroup取得了稳定且一致的结果,调整后的兰德指数在+0.80至+0.92之间,入侵者检测率在86%至94%之间。与单独基于混合模型的聚类相比,共识聚类提高了稳定性和临床一致性。与基线混合模型相比,统计收缩提高了聚类的稳定性以及交叉验证对数似然值。

结论

所提出的算法在对个体病例报告进行聚类时能够实现足够的稳定性和临床一致性,从而在药物警戒中更好地识别病例系列和相关的不良事件概况。经验贝叶斯收缩法和共识聚类的使用均在性能上带来了有意义的改进。

相似文献

1
Consensus clustering for case series identification and adverse event profiles in pharmacovigilance.药物警戒中用于病例系列识别和不良事件概况的一致性聚类分析
Artif Intell Med. 2021 Dec;122:102199. doi: 10.1016/j.artmed.2021.102199. Epub 2021 Oct 22.
2
Risk Factor Considerations in Statistical Signal Detection: Using Subgroup Disproportionality to Uncover Risk Groups for Adverse Drug Reactions in VigiBase.统计信号检测中的风险因素考虑:使用亚组不均衡性揭示 VigiBase 中药物不良反应的风险人群。
Drug Saf. 2020 Oct;43(10):999-1009. doi: 10.1007/s40264-020-00957-w.
3
Data-Driven Identification of Adverse Event Reporting Patterns for Japan in VigiBase, the WHO Global Database of Individual Case Safety Reports.基于个体病例安全报告的全球数据库(世卫组织全球数据库)的 Vigibase 中的数据驱动型日本不良事件报告模式识别。
Drug Saf. 2019 Dec;42(12):1487-1498. doi: 10.1007/s40264-019-00861-y.
4
A Feasibility Study of Drug-Drug Interaction Signal Detection in Regular Pharmacovigilance.常规药物警戒中药物-药物相互作用信号检测的可行性研究
Drug Saf. 2020 Aug;43(8):775-785. doi: 10.1007/s40264-020-00939-y.
5
Identification of Substandard Medicines via Disproportionality Analysis of Individual Case Safety Reports.通过个体病例安全报告的不成比例分析识别不合格药品。
Drug Saf. 2017 Apr;40(4):293-303. doi: 10.1007/s40264-016-0499-5.
6
Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.瑞士的药物性肝损伤:来自 2010 年至 2020 年世界卫生组织药物警戒数据库 VigiBase的与药物相关的肝障碍分析。
Swiss Med Wkly. 2021 May 12;151:w20503. doi: 10.4414/smw.2021.20503. eCollection 2021 May 10.
7
Data mining methodology for response to hypertension symptomology-application to COVID-19-related pharmacovigilance.数据挖掘方法在高血压症状反应中的应用-在 COVID-19 相关药物警戒中的应用。
Elife. 2021 Nov 23;10:e70734. doi: 10.7554/eLife.70734.
8
Disproportionality Analysis for Pharmacovigilance Signal Detection in Small Databases or Subsets: Recommendations for Limiting False-Positive Associations.药品不良反应信号检测中小数据库或子数据集的不均衡性分析:限制假阳性关联的建议。
Drug Saf. 2020 May;43(5):479-487. doi: 10.1007/s40264-020-00911-w.
9
Contribution of Causality Assessment for an Automated Detection of Safety Signals: An Example Using the French Pharmacovigilance Database.因果关系评估对自动检测安全信号的贡献:用法语药物警戒数据库举例。
Drug Saf. 2020 Mar;43(3):243-253. doi: 10.1007/s40264-019-00887-2.
10
Improved statistical signal detection in pharmacovigilance by combining multiple strength-of-evidence aspects in vigiRank.通过在vigiRank中结合多个证据强度方面来改进药物警戒中的统计信号检测。
Drug Saf. 2014 Aug;37(8):617-28. doi: 10.1007/s40264-014-0204-5.

引用本文的文献

1
Temporal Changes in Reporting of Neurodevelopmental Outcomes After Maternal Exposure to Valproate: A Contribution of the ConcePTION Project.孕期暴露于丙戊酸盐后神经发育结局报告的时间变化:受孕项目的一项贡献
Drug Saf. 2025 Jul 7. doi: 10.1007/s40264-025-01583-0.
2
Clinical Relatedness and Stability of vigiVec Semantic Vector Representations of Adverse Events and Drugs in Pharmacovigilance.药物警戒中不良事件和药物的vigiVec语义向量表示的临床相关性和稳定性
Drug Saf. 2025 Apr;48(4):401-413. doi: 10.1007/s40264-024-01509-2. Epub 2025 Jan 20.
3
A Clustering Ensemble Method for Drug Safety Signal Detection in Post-Marketing Surveillance.
一种用于上市后监测中药物安全信号检测的聚类集成方法。
Ther Innov Regul Sci. 2025 Jan;59(1):89-101. doi: 10.1007/s43441-024-00705-7. Epub 2024 Oct 20.
4
Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System.揭示药物诱导冲动性的负担:FDA 不良事件报告系统的网络分析。
Drug Saf. 2024 Dec;47(12):1275-1292. doi: 10.1007/s40264-024-01471-z. Epub 2024 Aug 15.
5
Editorial: Leveraging pharmacovigilance data mining with "the patient" in mind.社论:在考虑“患者”的情况下利用药物警戒数据挖掘
Front Pharmacol. 2022 Aug 15;13:980645. doi: 10.3389/fphar.2022.980645. eCollection 2022.
6
Post-Marketing Safety Profile of Vortioxetine Using a Cluster Analysis and a Disproportionality Analysis of Global Adverse Event Reports.基于全球不良事件报告的聚类分析和不适当比例分析的文拉法辛上市后安全性概况。
Drug Saf. 2022 Feb;45(2):145-153. doi: 10.1007/s40264-021-01139-y. Epub 2022 Jan 12.